Coronary Artery Disease Market Analysis, Size, Share & Growth Forecast 2026–2034

Ticagrelor PLATO Trial 20 Percent Cardiovascular Event Superiority Over Clopidogrel in ACS With Less Stent Thrombosis Has Made the Reversible P2Y12 Inhibitor the Preferred ADP Receptor Blocker for the NSTEMI and STEMI Patient Who Requires More Potent and Reliable P2Y12 Blockade.Novartis's inclisiran RNA interference therapy demonstrated 50% LDL reduction maintained over three years with only two injections annually after an initial loading dose, achieving PCSK9 inhibitor-comparable LDL lowering with a dosing frequency that substantially improves long-term adherence compared with biweekly monoclonal antibodies. The mechanism uses hepatic GalNAc-conjugated siRNA that permanently silences PCSK9 mRNA for six months per injection through RISC incorporation, creating a pharmacodynamic profile that is completely insensitive to patient daily adherence after injection administration. ORION-10 showed 17.9% absolute LDL reduction on top of maximally tolerated statin, and VICTORION-2 PREVENT is testing whether inclisiran reduces MACE outcomes in high-risk patients with persistent LDL above guideline targets despite optimal statin therapy.

FOURIER and ODYSSEY PCSK9 Inhibitor Evolocumab and Alirocumab 15 to 20 Percent CV Event Reduction With 60 Percent Additional LDL Reduction From Statin Baseline Has Established the LDL Below 55 mg/dL Target That Very High-Risk Post-MI Patients Require Beyond What Statin Monotherapy Can Achieve.Despite high-intensity atorvastatin reducing LDL by 50-55% and achieving guideline targets in the majority of treated patients, residual MACE risk remains substantial with approximately 10-15% annual event rates in very-high-risk secondary prevention patients, driving clinical investigation of triglyceride-lowering, lipoprotein(a)-lowering, and inflammation-targeting mechanisms. Amarin's icosapentaenoic acid Vascepa demonstrated 25% MACE reduction on top of statin therapy in REDUCE-IT through mechanisms that may extend beyond triglyceride-lowering to EPA membrane incorporation that stabilises coronary plaques. Lipoprotein(a) reduction through Amgen's olpasiran and Eli Lilly's lepodisiran antisense programmes is advancing to address the genetically determined Lp(a) elevation that affects approximately 20% of the population and doubles cardiovascular risk despite optimal LDL control.

Inclisiran Twice-Yearly siRNA PCSK9 Knockdown 52 Percent LDL Reduction From 2 Injections Per Year Has Provided the Durable LDL Lowering That the Monthly Antibody Injection Alternative Cannot Match for the Adherence Advantage That Biannual Dosing Provides.Ultrathin strut drug-eluting stents from Biotronik Orsiro and Boston Scientific Combined effect demonstrated lower rates of target-lesion failure compared with prior-generation stents in BIOFLOW-V and EVOLVE Short DAPT trials, establishing that strut thickness below 80 microns reduces the degree of flow disturbance that contributes to stent thrombosis and in-stent restenosis. Bioresorbable scaffold technology after the initial failures of Abbott Absorb is being re-approached by companies including Elixir Medical and Amaranth Medical with improved polymer composition, strut thinning, and accelerated resorption timelines that aim to resolve the adverse late outcomes seen with first-generation bioresorbable vascular scaffolds. Imaging-guided PCI with FFR assessment and IVUS or OCT is increasingly standard in complex multi-vessel disease, and ISCHEMIA data has refined the patient selection for PCI versus medical therapy that guides catheterisation laboratory referral decisions.

For related market intelligence, see the Cardiology Drug Market.